After receiving approval by the China Securities Regulatory Commission in August 1999, the company issued 58 million A shares on the open market. In October, the company's shares were then listed on the Shanghai Stock Exchange. As of the end of 2018, the company had 960 million yuan in registered capital and total assets of 10 billion yuan.
Zhejiang Medicine currently has nine major subsidiaries, including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang LaiYi Medicine Co., Ltd., Zhejiang Novus Pharmaceuticals Co., Ltd., Zhejiang Changhai Pharmaceuticals Co., Ltd., Shanghai Vital Health Management Co., Ltd., NovoCodex Biopharmaceuticals. Co., Ltd., and two research units, the Pharmaceutical Industry Research Institute and the Shanghai Laiyi Biopharmaceutical R&D Center. The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees.
At present, Zhejiang Medicine performs the specialized and large-scale production of fat-soluble vitamins, retinoids, quinolone antibiotics, anti-resistance antibiotics, and other products. The company's leading products, including its synthetic vitamin E, natural vitamin E, β-carotene, cantharidin, vancomycin hydrochloride, and teicoplanin all rank among the top worldwide. The company's preparations of injectable levofloxacin lactate (trade name "Lailixin"), injectable vancomycin hydrochloride injection (trade name "Laikexin"), and injectable teicoplanin (trade name "Jialixin") occupy important positions in the Chinese market.
Zhejiang Medicine adheres to a development strategy of "Innovation and Entrepreneurship, Competitive Development, Advanced Development, and Strength through Talent". The company focuses on product development, places great importance on restructuring, integrates a number of resources, strengthens indigenous technology innovation and technology innovation to produce the best possible products, performs high-level DMF file registration and FDA certification procedures, vigorously promotes clean production and the circular economy, is building a complete market network from a global perspective, and has developed a positive brand image and advanced corporate culture, thus enhancing the company’s core competitiveness. At present, Zhejiang Medicine has developed into a technologically-advanced, large-scale, and globally influential and competitive pharmaceutical company.